Cargando…

Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis

BACKGROUND: The objective of this study was to characterize insulin use and examine factors associated with persistence to mealtime insulin among patients with type 2 diabetes (T2D) on stable basal insulin therapy initiating mealtime insulin therapy. METHODS: Insulin use among patients with T2D init...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonafede, Machaon M, Kalsekar, Anupama, Pawaskar, Manjiri, Ruiz, Kimberly M, Torres, Amelito M, Kelly, Karen R, Curkendall, Suellen M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025898/ https://www.ncbi.nlm.nih.gov/pubmed/21226935 http://dx.doi.org/10.1186/1472-6823-11-3

Ejemplares similares

A retrospective database analysis of insulin use patterns in insulin-naïve patients with type 2 diabetes initiating basal insulin or mixtures
por: Bonafede, Machaon MK, et al.
Publicado: (2010)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
por: Johnson, Mary L., et al.
Publicado: (2022)

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009)

Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes
por: Jain, S M, et al.
Publicado: (2010)

Retrospective Analysis of Long-Term Adherence to and Persistence with DPP-4 Inhibitors in US Adults with Type 2 Diabetes Mellitus
por: Farr, Amanda M., et al.
Publicado: (2014)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin
por: Evans, Marc, et al.
Publicado: (2019)

Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis
por: Shi, Lizheng, et al.
Publicado: (2010)

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

The Burden and Impacts of Mealtime Insulin from the Perspective of People with Diabetes
por: Paczkowski, R., et al.
Publicado: (2023)

Correction to: The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen
por: Castellano, Elena, et al.
Publicado: (2018)

Patient Perceptions and Preferences for a Mealtime Insulin Delivery Patch
por: Peyrot, Mark, et al.
Publicado: (2018)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study
por: Bolli, Geremia B., et al.
Publicado: (2009)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Mealtime fast‐acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin‐resistant Type 2 diabetes
por: Bowering, K., et al.
Publicado: (2018)

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial
por: Davies, M J, et al.
Publicado: (2014)

Daily injection of melatonin inhibits insulin resistance induced by chronic mealtime shift
por: Park, Jihyun, et al.
Publicado: (2022)

Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes
por: Lane, Wendy, et al.
Publicado: (2021)

Short Report: Treatment Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal–Bolus Type 1): 2-year results of a randomized clinical trial
por: Bode, B W, et al.
Publicado: (2013)

Safety and Effectiveness of Switching from a Basal-only to Biphasic Insulin Aspart 30 Insulin Regimen
por: Haddad, Jihad, et al.
Publicado: (2013)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Abstract 21: The burden of mealtime insulin dosing in adults and children with type 1 diabetes
por: Revanna, Manjunatha, et al.
Publicado: (2022)

Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
por: Raccah, D., et al.
Publicado: (2017)

Improving the Estimation of Mealtime Insulin Dose in Adults With Type 1 Diabetes: The Normal Insulin Demand for Dose Adjustment (NIDDA) study
por: Bao, Jiansong, et al.
Publicado: (2011)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
por: Hirsch, I. B., et al.
Publicado: (2016)

Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes
por: Slabaugh, S. Lane, et al.
Publicado: (2015)

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
por: Detournay, Bruno, et al.
Publicado: (2020)

Future of newer basal insulin
por: Madhu, S. V., et al.
Publicado: (2013)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
por: Shafie, Asrul Akmal, et al.
Publicado: (2020)

Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
por: Seufert, Jochen, et al.
Publicado: (2019)

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1)
por: Matsuhisa, M., et al.
Publicado: (2016)

Mealtime insulin BOLUS score increases prior to clinic visits in youth with type 1 diabetes
por: McConville, Andrew, et al.
Publicado: (2020)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
por: Tosaka, Yuka, et al.
Publicado: (2015)

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A ≥52-week randomized, double-blind study
por: Yki-Järvinen, Hannele, et al.
Publicado: (2013)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_io7rs68go63eoo66q1uii63tpp